We’ve occasionally been bagged at MM for not being unwavering disciples of CSL, criticism we believe is unfair as we haven’t knocked this business just the share price from a valuation perspective i.e. I can argue that the stock remaining 11% below its 2020 is testament to our price concerns. Discussing this healthcare goliath I have recently found myself describing it as boring at times but after appearing to complete an almost 30% correction this year we believe value has returned to the quality stock i.e. we are bullish looking for another challenge of the $350 area. We own CSL in our Flagship Growth Portfolio.
MM remains long and bullish CSL
Add To Hit List
